The Amicus acquisition will bolster BioMarin’s rare disease portfolio, while potentially growing the company’s future revenue ...

The Indian Medical Parliamentarians’ Forum (IMPF), a cross-party collective of 45 medical professionals turned ...

In a merger of rare disease specialists, BioMarin has agreed to acquire Amicus Therapeutics for $4.8 billion. The California ...

The Indian Medical Parliamentarians Forum has urged urgent government action to prevent life-threatening treatment ...

A couple struggling to access a vital cancer treatment say they are "extremely stressed" by the uncertainty in its supply.

BioMarin Pharmaceutical’s strong rare disease drug portfolio and Amicus acquisition drive a ‘Buy’ rating. Click here to read my latest analysis of BMRN stock.

Takeda reports positive Phase 3 data for psoriasis drug zasocitinib, beating placebo and Otezla, with rapid PASI responses ...

Elfabrio (R) (pegunigalsidase alfa for injection) is an enzyme replacement therapy indicated for the longterm treatment of adult patients with a confirmed diagnosis of Fabry disease (deficiency of ...

Important Safety Information Indication Elfabrio ® (pegunigalsidase alfa for injection) is an enzyme replacement therapy indicated for the longterm treatment of adult patients with a confirmed ...

Amid news of the splashy $4.8 billion Amicus buy, BioMarin has slipped in the discontinuation of a genetic liver disease ...

India’s rare disease care relies on crowdfunding as costly therapies outstrip public support. Government aid is capped and ...